Cervical Cancer Diagnostic Market To Reach $7.0 Billion By 2030

Cervical Cancer Diagnostic Market Growth & Trends

The global cervical cancer diagnostic market size is expected to reach USD 7.0 billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030, according to a new study conducted by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.

 Request a free sample copy or view report summary: Cervical Cancer Diagnostic Market Report

Cervical Cancer Diagnostic Market Report Highlights

• In 2022, the Pap testing segment held majority of the market share of 33.06%. The segment’s large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.

• In 2022, North America was the leading regional market with a revenue share of 45.74%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country’s large market share.

• Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 8.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region’s high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth

• This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

Cervical Cancer Diagnostic Market Segmentation

Grand View Research has segmented the global cervical cancer diagnostic market on the basis of type, age-group, end use, and region

Cervical Cancer Diagnostic Test Type Outlook (Revenue in USD Million, 2018 - 2030)

• Pap Testing (Cytology Testing)

• HPV Testing

• Colposcopy

• Cervical Biopsies

• Cystoscopy

Cervical Cancer Diagnostic Age Group Outlook (Revenue in USD Million, 2018 - 2030)

• 20-40 years

• Above 40 years

Cervical Cancer Diagnostic End Use Outlook (Revenue in USD Million, 2018 - 2030)

• Hospitals

• Laboratories

• Diagnostic centers

Cervical Cancer Diagnostic Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Cervical Cancer Diagnostic Market

• Abbott Laboratories

• Quigan NV

• Thermo Fisher Scientific Inc

• Carl Zeiss AG

• Dickinson and Company

• Hologic Inc

• CooperSurgical Inc

• Siemens Healthineers